Edinburgh MedTech Firm Trogenix Secures £70M for Cancer Therapy Breakthroughs
Edinburgh-based MedTech firm Trogenix has secured £70 million in a Series A funding round. The investment will bolster the company's mission to develop next-generation cancer therapies targeting aggressive solid tumours. Trogenix's proprietary Odysseus platform, which aims to kill cancer cells while sparing healthy tissue, will also be enhanced with the investment.
Trogenix, founded two years ago by Dr. Emily Carter, has made significant strides in its cancer-fighting technology. The company's lead programme is focused on glioblastoma, with a follow-on programme targeting colorectal cancer liver metastases. The investment will accelerate the development of these programmes, with the lead glioblastoma programme set to enter clinical trials in Q1 2026.
The funding will also support the expansion of Trogenix's pipeline in liver and lung cancers. CEO Ken Macnamara stated that the investment will advance their lead and follow-on programmes through the clinic, furthering Trogenix's goal of creating innovative, effective cancer treatments.
Trogenix's £70 million Series A funding will fuel the development of its Odysseus platform and cancer therapies targeting aggressive solid tumours. With the lead glioblastoma programme poised to enter clinical trials in early 2026, the investment brings Trogenix's innovative approach to cancer treatment a significant step closer to patients.
Read also:
- Israel announces the development of a laser-based anti-missile and drone countermeasure system
- Most Potent Nuclear Explosive Ever Constructed - Tsar Bomba
- Enhanced ceramic material through humidity significantly boosts fuel cell efficiency, study contends
- Exploring the Colorful World of Magnetic Forces: Unveiling the Mysteries of Attraction and Repulsion Throughout the Spectrum
